A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Myelodysplastic syndromes (MDS) are a group of conditions where the bone marrow struggles to make healthy red blood cells, often causing severe anaemia. Many people need regular blood transfusions to stay well, but standard medicines called ESAs do not always work or may stop working over time. This trial is looking at a medicine named imetelstat. Researchers want to find out whether imetelstat can help people with lower-risk MDS go without blood transfusions for at least 8 weeks in a row, and potentially longer. The study also tracks safety, side effects, overall health, and how well bone marrow functions over time. Half of the participants in the main phase receive the active drug, while others may receive a dummy treatment (placebo) to ensure fair comparison.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
Myelodysplastic syndromes, or MDS, affect how your bone marrow produces blood cells. When the body cannot make enough healthy red blood cells, severe tiredness and breathlessness can occur. For many people with MDS, regular blood transfusions become an essential part of daily life to keep energy levels up. However, needing frequent transfusions can take a toll on quality of life and lead to other health complications.
While there are standard medicines designed to encourage the body to make more red blood cells, these treatments do not work for everyone, or they can lose their effect over time. When this happens, doctors have fewer options to offer. This clinical trial is testing a new treatment called imetelstat to see if it can help break this cycle.
Imetelstat works in a different way to standard treatments. Researchers want to know if it can help the bone marrow recover enough to produce its own red blood cells again. If successful, this could mean participants need far fewer transfusions, or even none at all for long periods, giving people more freedom and a better quality of life.
النقاط الرئيسية
- Tests a new medicine called imetelstat for adults with lower-risk MDS.
- Aimed at people who depend on frequent red blood cell transfusions.
- Designed for those whose anaemia has not improved with standard treatments.
- A key goal is helping patients go at least 8 weeks without a transfusion.
- المشاركة طوعية، ويمكنك الانسحاب في أي وقت.
من قد يكون مؤهلاً؟
This study is open to adults aged 18 and over who have been diagnosed with lower-risk or intermediate-risk myelodysplastic syndrome (MDS). To be considered, you must currently depend on regular red blood cell transfusions to manage your anaemia.
In addition, standard treatments—specifically medicines known as erythropoiesis-stimulating agents (or ESAs)—must have either stopped working for you or failed to help in the first place.
A doctor or study team will review your full medical history, blood results, and general organ health to ensure that taking part in the trial is safe and suitable for your specific situation.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- عمري 18 عامًا أو أكثر.
- I have been diagnosed with low or intermediate-risk MDS.
- I need regular red blood cell transfusions to manage my anaemia.
- Standard ESA treatments have either stopped working or did not work for me.
- I am able and willing to attend regular hospital appointments for treatment and tests.
ماذا يتضمن المشاركة؟
Taking part involves receiving either the study medicine (imetelstat) or an inactive dummy treatment (placebo) given through an intravenous drip into a vein. Because this is a controlled trial, neither you nor your doctor will know which treatment you are receiving at first, which ensures the results are completely unbiased.
You will have regular hospital visits for health checks. These include routine blood tests, checks on your vital signs (such as blood pressure and heart rate), heart tracings (ECGs), and monitoring how many blood transfusions you need. The study team will track your health closely to see if you can go at least 8 to 24 weeks without needing a transfusion. The study lasts for several months, followed by long-term check-ins to monitor your health and wellbeing.
المخاطر والفوائد المحتملة
المواقع (8)
- —غير مؤكدألمانيا
- —غير مؤكدإيطاليا
- —غير مؤكدالتشيك
- —غير مؤكدفرنسا
- —غير مؤكدهولندا
- —غير مؤكدبلجيكا
- —غير مؤكدإسبانيا
- —غير مؤكدبولندا
أسئلة شائعة
What is imetelstat?
Imetelstat is an experimental medicine designed to treat certain bone marrow disorders by targeting abnormal cells and helping the body produce healthier blood cells.
What is the main goal of this trial?
The primary goal is to find out if imetelstat can help people go for at least 8 continuous weeks without needing a red blood cell transfusion.
Will I definitely receive the new medicine?
Not necessarily. In part of the trial, participants are randomly assigned by a computer to receive either imetelstat or a dummy drip (placebo) to ensure the study provides reliable results.
Can I still have blood transfusions if I need them?
Yes. Your safety and comfort come first. If your blood counts drop and you need a transfusion, your doctors will give you one immediately.
هل يمكنني مغادرة الدراسة مبكرًا؟
Yes. You have the right to withdraw from the trial at any point, for any reason, and your regular medical team will continue to look after you.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.